Dirk Thye - 19 May 2022 Form 4/A - Amendment Insider Report for Cortexyme, Inc. (QNCX)

Role
Chief Executive Officer, Director
Signature
/s/ Chris Lowe, Attorney-in-Fact for Dirk Thye
Issuer symbol
QNCX
Transactions as of
19 May 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
27 May 2022, 17:35:51 UTC
Date Of Original Report
23 May 2022
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNCX Common Stock Award $0 +216,322 +335% $0.000000 280,911 19 May 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest monthly, subject to continued service.
F2 On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.

Remarks:

Due to an administrative error, the transaction reported in this Form 4 was inadvertently omitted from the original filing. The total amount of shares owned is reported as of May 19, 2022.